Topiramate
Topiramate is an oral antiepileptic and migraine prophylactic used in adults and children. It has multiple mechanisms including sodium channel blockade and GABA enhancement, and is also approved as an adjunct for partial-onset and generalised seizures.
- Chemical formula
- C12H21NO8S
- CAS number
- 97240-79-4
- ATC code
- N03AX11
- Molecular weight
- 339.36 g/mol
- Drug class
- Antiepileptic (sulfamate-substituted monosaccharide)
- Also known as
- RWJ-17021, Topiramato
What is it?
Topiramate was approved as an antiepileptic in 1996 and for migraine prophylaxis in 2004. It is supplied as oral tablets, capsules and extended-release capsules. Topiramate is dispensed only on prescription and is widely used in epilepsy, migraine and (in combination products) weight management. Multiple authorised generics are now available worldwide.
Mechanism of action
Topiramate is a sulfamate-substituted monosaccharide with multiple mechanisms of action: blockade of voltage-gated sodium channels, enhancement of gamma-aminobutyric acid (GABA) activity at non-benzodiazepine GABA-A receptor sites, antagonism of glutamate at AMPA/kainate receptors, and weak inhibition of carbonic anhydrase. This multimodal action explains its efficacy across epilepsy, migraine and other neurological indications.
Pharmacokinetics
Oral topiramate is well absorbed, with bioavailability of approximately 80%. Plasma protein binding is low (around 15%). The drug is excreted predominantly unchanged in urine, with hepatic metabolism becoming more important when topiramate is co-administered with enzyme inducers. The plasma half-life is approximately 21 hours, supporting twice-daily dosing or once-daily extended-release formulations. Renal impairment requires dose reduction.
Indications
Topiramate is approved in adults and children for the treatment of partial-onset seizures, primary generalised tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome (as adjunctive or monotherapy depending on the country and indication). It is also approved for migraine prophylaxis in adults. According to international guidelines, topiramate is one of the recommended first-line agents for migraine prevention.
Safety profile
Common adverse effects include paraesthesia, fatigue, dizziness, anorexia and weight loss, and cognitive symptoms (word-finding difficulties, concentration problems). Specific adverse effects include metabolic acidosis, kidney stones, acute angle-closure glaucoma (rare but serious), oligohidrosis with hyperthermia (particularly in children) and an increased risk of cleft palate when used in early pregnancy. According to the prescribing information, topiramate should not be used during pregnancy unless the benefits clearly outweigh the risks.
Products containing this ingredient
Frequently asked questions
Why is topiramate used for migraine prevention? ▾
Multiple randomised trials have shown that topiramate at doses of 50-100mg per day reduces migraine frequency in adults with episodic and chronic migraine. According to international guidelines, it is one of the recommended first-line agents for migraine prevention, alongside beta-blockers and CGRP-targeted agents. The choice depends on individual response, comorbidities and tolerability, with the prescriber making the final decision.
Why does topiramate cause weight loss? ▾
Anorexia and weight loss are common adverse effects of topiramate, more pronounced at higher doses and during prolonged treatment. The mechanism is not fully understood and may relate to taste alteration, satiety changes and metabolic effects. Combination products with phentermine are approved for weight management in some markets. According to the prescribing information, weight should be monitored during treatment.
Why is acute glaucoma a concern with topiramate? ▾
Topiramate has been associated with an idiosyncratic syndrome of acute myopia and secondary angle-closure glaucoma, typically occurring within the first month of treatment. Symptoms include blurred vision, ocular pain and headache. According to the prescribing information, patients with these symptoms should stop topiramate and seek immediate ophthalmological evaluation. Untreated angle-closure glaucoma can cause permanent vision loss.
Is topiramate safe in pregnancy? ▾
No. Topiramate is associated with an increased risk of major birth defects, particularly cleft lip and palate, when used during the first trimester. Several regulatory agencies have issued warnings or restrictions for use in women of childbearing potential. According to the prescribing information, effective contraception is required during treatment, and topiramate should not be used during pregnancy unless the benefits clearly outweigh the risks. The prescriber must review reproductive plans.
What are the main contraindications for topiramate? ▾
Topiramate is contraindicated in known hypersensitivity to topiramate or its excipients, in pregnancy for migraine prophylaxis (and recommended only when benefits outweigh risks for epilepsy), and in concurrent use with alcohol with extended-release products. Caution is required in renal and hepatic impairment, kidney stone history, glaucoma risk, and during pregnancy and breastfeeding. According to the prescribing information, the medical history must be reviewed by a clinician before any prescription.
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.